Literature DB >> 23623807

Targeting T cells to tumor cells using bispecific antibodies.

Stanley R Frankel1, Patrick A Baeuerle.   

Abstract

The immune system, and in particular T cells, can be harnessed to treat cancer. Several bispecific T cell engaging antibodies of the BiTE® format are in early or late-stage clinical development. These small recombinant antibody constructs effectively trigger killing of cancer cells by temporarily attached, polyclonal T cells. Blinatumomab, a CD19/CD3-bispecific BiTE® antibody, has demonstrated high clinical activity in B cell leukemia and lymphoma patients. Three additional BiTE antibodies directed against surface target antigen expressed on solid tumors are being evaluated in phase I clinical trials. Alternative approaches to direct polyclonal T cells to kill cancer cells are under intense investigation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23623807     DOI： 10.1016/j.cbpa.2013.03.029

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN： 1367-5931            Impact factor:   8.822


  65 in total

1.  A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.

Authors:  Weihua Hou; Qingyun Yuan; Xingxing Yuan; Yuxiong Wang; Wei Mo; Huijie Wang; Min Yu
Journal:  Invest New Drugs       Date:  2018-12-04       Impact factor: 3.850

Review 2.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

3.  Chemical biology: How to minimalize antibodies.

Authors:  Christoph Rader
Journal:  Nature       Date:  2015-02-05       Impact factor: 49.962

4.  Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.

Authors:  Junpeng Qi; Xiuling Li; Haiyong Peng; Erika M Cook; Eman L Dadashian; Adrian Wiestner; HaJeung Park; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

Review 5.  Bispecific antibodies in cancer immunotherapy.

Authors:  Siqi Chen; Jing Li; Qing Li; Zhong Wang
Journal:  Hum Vaccin Immunother       Date:  2016-06-01       Impact factor: 3.452

Review 6.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

7.  Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Authors:  Tao Dao; Dmitry Pankov; Andrew Scott; Tatyana Korontsvit; Victoriya Zakhaleva; Yiyang Xu; Jingyi Xiang; Su Yan; Manuel Direito de Morais Guerreiro; Nicholas Veomett; Leonid Dubrovsky; Michael Curcio; Ekaterina Doubrovina; Vladimir Ponomarev; Cheng Liu; Richard J O'Reilly; David A Scheinberg
Journal:  Nat Biotechnol       Date:  2015-09-21       Impact factor: 54.908

8.  Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity.

Authors:  Katarzyna C Pituch; Markella Zannikou; Liliana Ilut; Ting Xiao; Michael Chastkofsky; Madina Sukhanova; Nicola Bertolino; Daniele Procissi; Christina Amidei; Craig M Horbinski; Karen S Aboody; C David James; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 9.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

10.  Chemically Programmed Bispecific Antibodies in Diabody Format.

Authors:  Even Walseng; Christopher G Nelson; Junpeng Qi; Alex R Nanna; William R Roush; Rajib K Goswami; Subhash C Sinha; Terrence R Burke; Christoph Rader
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.